Why the study?
It was unknown whether platelet reactivity on clopidogrel therapy measured by a point-of-care assay is associated with thrombotic events after PCI with drug-eluting stents.
Does high post-treatment platelet reactivity on clopidogrel increase the risk of thrombotic events in patients undergoing PCI with drug-eluting stents?
Does high post-treatment platelet reactivity on clopidogrel increase the risk of thrombotic events in patients undergoing PCI with drug-eluting stents?
Answers are grounded in this paper and cite their sources.
High post-treatment platelet reactivity on clopidogrel, assessed by a point-of-care assay, is associated with an increased risk of ischemic events including stent thrombosis after PCI with drug-eluting stents.
AIMS: The aim of this study was to determine whether platelet reactivity on clopidogrel therapy, as measured by a point-of-care platelet function assay, is associated with thrombotic events after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). METHODS AND RESULTS: Platelet reactivity on clopidogrel (post-treatment reactivity) was measured with the VerifyNow P2Y12 assay (Accumetrics Inc., San Diego, CA, USA) in 380 patients undergoing PCI with sirolimus-eluting stents. Receiver-operating characteristic curve analysis was used to derive the optimal cut-off value for post-treatment reactivity in predicting 6 month out-of-hospital cardiovascular (CV) death, non-fatal MI, or stent thrombosis. The mean post-treatment reactivity was 184 +/- 85 PRU (P2Y12 reaction units). The optimal cut-off for the combined endpoint was a post-treatment reactivity > or =235 PRU [area under the curve 0.711 (95% confidence interval 0.529-0.893), P = 0.03], which was similar to the threshold of the upper tertile (231 PRU). Patients with post-treatment reactivity greater than the cut-off value had significantly higher rates of CV death (2.8 vs. 0%, P = 0.04), stent thrombosis (4.6 vs. 0%, P = 0.004), and the combined endpoint (6.5 vs. 1.0%, P = 0.008). CONCLUSION: High post-treatment platelet reactivity measured with a point-of-care platelet function assay is associated with post-discharge events after PCI with DES, including stent thrombosis. Investigation of alternative clopidogrel dosing regimens to reduce ischaemic events in high-risk patients identified by this assay is warranted.
No takes yet. Share an insight, caveat, or question.
Price et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: